RxDoctor Payments Data

Donna Marchant, MD

Cardiovascular Disease · Manhasset, NYNPI 1275603318

Payments from drug & device makers

$1,665in general payments, 2019–2025

Across 75 payments — averaging $22.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$597
  • Amgen$216
  • Pfizer$147
  • Edwards Lifesciences$141
  • E.r. Squibb & Sons, L.L.C.$135
  • Medtronic$125
  • plus $305 from 6 others

What the payments were for

  • Food & beverage$1,57094%
  • Education$956%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,665 in reported general payments places this provider in the 50th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$307,511
Medicare patients
2,311
Services billed
7,044

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban722$868,709
EntrestoSacubitril/Valsartan129$172,986
XareltoRivaroxaban123$172,773
FarxigaDapagliflozin Propanediol77$84,070
MultaqDronedarone Hcl37$70,296
Repatha SureclickEvolocumab62$43,495
Praluent PenAlirocumab43$29,408
Metoprolol Succinate1,468$21,104
JardianceEmpagliflozin12$17,608
JanuviaSitagliptin Phosphate11$17,572
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$10,974
Atorvastatin Calcium910$9,881
BrilintaTicagrelor13$9,009
Rosuvastatin Calcium580$7,964
CrestorRosuvastatin Calcium14$5,988

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$147$868,709722 claims
NovartisEntresto$597$172,986129 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in Manhasset

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →